SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending due to a high-conviction short squeeze thesis, with retail investors highlighting its small float and significant short interest relative to its available shares. Community members are actively debating the stock's potential for a massive move, frequently comparing its technical setup to other major short squeeze plays and weighing it against competitors in the fast-food sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing significant downward pressure as investors rotate out of semiconductor stocks following a massive sector-wide rally and reports that Meta is considering monetizing excess AI compute capacity. Community discussion remains polarized, with many retail traders viewing the volatility as a routine accumulation opportunity and long-term buying window, while others express concern over softening AI infrastructure demand and potential competition from alternative memory suppliers.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is rallying following reports that the company plans to launch a cloud-computing division to monetize excess AI infrastructure, shifting investor perception from seeing its heavy capital expenditure as a pure cost toward a potential revenue-generating asset. Community sentiment is deeply divided, with bulls viewing this as a strategic ROI catalyst that justifies recent infrastructure investments, while bears remain skeptical, dismissing the move as a desperate mitigation strategy for overbuilt capacity and failed prior initiatives.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group stock is experiencing high volatility as investors react to reports of Meta potentially entering the cloud infrastructure market, which has sparked concerns about future demand and competition for compute capacity. While bears worry that Meta's internal cloud expansion could pressure margins or reduce reliance on neocloud providers, many community members argue the selloff is an overreaction to a long-term supply-constrained market where existing multi-billion dollar contracts ensure demand remains robust.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is attracting significant community attention as investors debate its role as an AI data licensing powerhouse, with many highlighting potential partnerships with major LLM providers as a long-term growth catalyst. Sentiment remains polarized, with retail bulls focusing on its unique data moat and institutional potential while others express frustration over persistent price volatility and the stock's tendency to trade in lockstep with broader software sector rotations.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory path for AXPAXLI, specifically focusing on whether the company will submit an NDA based on a single pivotal trial. While community sentiment remains split between bullish excitement over potential market disruption and bearish concerns regarding clinical trial design, the stock remains a focal point for institutional accumulation and acquisition speculation.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is currently experiencing significant market momentum fueled by the launch of Ford Energy and strategic partnerships aimed at positioning the automaker within the grid-scale power and data center infrastructure sector. Community discussion is focused on the potential for long-term valuation rerating, with many traders analyzing institutional call option activity and upcoming product reveals as catalysts for continued upside.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is trending as retail investors grapple with extreme volatility driven by a major rebalancing of Korean National Pension Service holdings and heavy speculation around AI memory chip suppliers. Community discussion remains polarized, with many traders debating whether recent sharp sell-offs represent a technical buying opportunity or the beginning of a larger correction in the broader semiconductor sector.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending downward following reports that Meta is developing an internal initiative to monetize its excess AI compute capacity, sparking investor concerns over potential future competition and long-term pricing power for neocloud providers. Despite the sell-off, the community is debating whether this signals a genuine supply glut or merely a strategic monetization of assets, with many long-term holders pointing to CoreWeave's ironclad, multi-year contracts as a buffer against near-term headline volatility.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors weigh significant operational progress, including the scheduled delivery of new AI data center capacity, against a broader sector sell-off triggered by concerns over hyperscaler compute supply. The community remains focused on the company's long-term contracted backlog and execution capabilities, actively debating whether the recent price volatility represents a strategic buying opportunity or a deeper shift in market sentiment toward AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James🏁 $TSHA Strong Buy/$13 
$NGNE $ACAD $ALPMY  
Raymond James said: 
Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. 
 
Raymond James added:

Peter Quick

Glide

Warren Collins

avalon E

Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. 
$NGNE $ACAD $ALPMY 
Citizens JMP added: 
A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett 
gene therapy competitor. 
 
We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: 
Overall, both TSHA &amp; NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. 
 
Based on the more involved procedure required for 
ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.

StockTwits Web

Taysha Gene Therapies Inc

Neurogene Inc

Acadia Pharmaceuticals Inc

ASTELLAS PHARMA/ADR

Quantumup

Cantor reit $TSHA OW13 
$NGNE $ACAD 
Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha&#39;s TSHA-102 (intrathecally administered AAV9-based gene therapy). 
 
NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE&#39;s release. 
 
While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don&#39;t fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a &quot;responder&quot; in their pivotal trial.

  
Raymond James said: 
Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. 
 
Raymond James added: